According to Zacks, “Innophos, Inc., is one of the leading North American manufacturers of specialty phosphates, serving a diverse range of customers across multiple applications, geographies and channels. Innophos offers a broad suite of products used in a wide variety of food and beverage, consumer products, pharmaceutical and industrial applications. Innophos’ market-leading positions derive from its experience and dedication to customer service and innovation. “
IPHS has been the subject of several other research reports. TheStreet cut ZovioInc . from a “c-” rating to a “d” rating in a research report on Thursday, May 23rd. BidaskClub raised Zai Lab from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $31.00.
NASDAQ IPHS opened at $27.69 on Thursday. Innophos has a twelve month low of $22.57 and a twelve month high of $50.40. The company has a quick ratio of 1.49, a current ratio of 3.14 and a debt-to-equity ratio of 0.95. The firm has a market cap of $541.71 million, a PE ratio of 12.30 and a beta of 1.41. The business’s 50-day simple moving average is $27.84.
Innophos (NASDAQ:IPHS) last posted its quarterly earnings data on Tuesday, April 30th. The specialty chemicals company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.14. Innophos had a return on equity of 13.09% and a net margin of 4.30%. The business had revenue of $191.41 million during the quarter, compared to analysts’ expectations of $199.90 million. During the same quarter in the previous year, the firm earned $0.61 EPS. The firm’s revenue was down 6.8% compared to the same quarter last year. As a group, sell-side analysts predict that Innophos will post 2.36 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of IPHS. WINTON GROUP Ltd raised its stake in Innophos by 47.2% during the 2nd quarter. WINTON GROUP Ltd now owns 12,493 shares of the specialty chemicals company’s stock worth $364,000 after buying an additional 4,008 shares during the period. Granite Investment Partners LLC raised its stake in Innophos by 4.4% during the 1st quarter. Granite Investment Partners LLC now owns 28,219 shares of the specialty chemicals company’s stock worth $851,000 after buying an additional 1,178 shares during the period. Hancock Whitney Corp raised its stake in Innophos by 164.2% during the 1st quarter. Hancock Whitney Corp now owns 47,196 shares of the specialty chemicals company’s stock worth $1,422,000 after buying an additional 29,329 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Innophos during the 1st quarter worth $542,000. Finally, GHP Investment Advisors Inc. raised its stake in Innophos by 18.9% during the 1st quarter. GHP Investment Advisors Inc. now owns 10,302 shares of the specialty chemicals company’s stock worth $311,000 after buying an additional 1,636 shares during the period. 93.43% of the stock is owned by hedge funds and other institutional investors.
Innophos Company Profile
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
Further Reading: Trading Options- What is a Strangle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.